Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Using Systemic Therapy in BCLC Stage B HCC

March 10th 2021

Assessing outcomes associated with systemic therapy, such as lenvatinib and sorafenib, for patients with BCLC (Barcelona Clinic Liver Cancer) stage B hepatocellular carcinoma based on data from the IMbrave150 and GIDEON trials.

Trastuzumab Deruxtecan Enters Treatment Paradigm for Gastrointestinal Cancer Subtypes

March 9th 2021

Trastuzumab deruxtecan represents a potential new standard of care for adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.

Expert Panel Considers Clinical Scenarios With Data Gaps in GI Malignancies

March 8th 2021

Cathy Eng, MD, FACP, FASCO, and Jordan D. Berlin, MD discuss pressing questions in hepatocellular carcinoma, colorectal cancer, gastric cancer, neuroendocrine tumors, and pancreatic cancer.

FDA Approval Insights: Trastuzumab Deruxtecan in HER2+ Metastatic Gastric/GEJ Cancer

March 8th 2021

Dr. Shitara discusses the significance of the FDA approval of trastuzumab deruxtecan in HER2-positive gastric and GEJ adenocarcinoma and key efficacy and safety data that have been reported with the agent.

Advanced Cholangiocarcinoma: Current Patient Prognosis

March 8th 2021

GI oncologists react to a prognosis for patients with newly diagnosed advanced cholangiocarcinoma and discuss how they counsel patients on goals of care and treatment expectations.

Cholangiocarcinoma: Importance of Adequate Tissue Collection

March 8th 2021

Best practices for working with other colleagues to ensure adequate tissue collection occurs when conducting a biopsy on a patient suspected of having cholangiocarcinoma, as well as considerations for next-generation sequencing.

Dr. Jones on Selecting Between Frontline Regimens in Pancreatic Cancer

March 5th 2021

Amy Jones, MD, discusses factors that can inform frontline treatment selection in pancreatic cancer.

Frontline Nivolumab Plus Chemo Shows Practice-Changing Potential in GI Cancers

March 5th 2021

Yelena Y. Janjigian, MD, discussed the promise of nivolumab plus chemotherapy in patients with PD-L1–positive advanced gastric cancer, GEJ cancer, and esophageal adenocarcinoma, as well as important biomarkers that should be used to guide sequencing decisions.

TACE and Systemic Therapy in HCC

March 5th 2021

An in-depth discussion about the role of TACE in combination with systemic therapies for the treatment of HCC.

Recent Findings in Systemic Therapy for Patients With BCLC Stage B HCC

March 5th 2021

Amit G. Singal, MD, MS, leads a review of recent data around the outcomes of systemic therapy for patients with BCLC stage B HCC.

Dr. Levy on Future Research Directions for Lenvatinib in HCC

March 4th 2021

Anna T. Levy, DO, discuses future research directions for lenvatinib in patients with hepatocellular carcinoma.

Dr. Philip on the Efficacy of TAS-102 in mCRC

March 4th 2021

Tony Philip, MD, discusses the efficacy of trifluridine/tipiracil in patients with metastatic colorectal cancer who are ineligible for intensive treatment.

Practical Considerations of TACE: Unresectable BCLC Stage B HCC

March 3rd 2021

Practical considerations for TACE (transarterial chemoembolization) in unresectable BCLC stage B HCC, including assessing radiologic response and determining when to initiate systemic therapy.

Patient Assessment for TACE in Unresectable BCLC Stage B HCC

March 3rd 2021

Examining individual patient assessment for using TACE (transarterial chemoembolization) in unresectable BCLC (Barcelona Clinic Liver Cancer) stage B hepatocellular carcinoma and the health care team involved.

Dr. Singal on the Utility of Frontline Lenvatinib and Sorafenib in Advanced HCC

March 2nd 2021

Amit G. Singal, MD, MS, discusses the utility of frontline lenvatinib and sorafenib in hepatocellular carcinoma.

Gastric/GEJ Cancers Gain Traction With HER2-Targeted Therapy With More to Come

March 2nd 2021

Daniel H. Ahn, DO, and Manish A. Shah, MD, discuss the emergence of HER2 as a validated target in GI malignancies, the approval of trastuzumab deruxtecan in gastric/GEJ cancer, and other emerging agents that are poised to propel HER2-targeted therapy in these diseases.

FDA Approval Sought for Ivosidenib in Previously Treated IDH1-Mutant Cholangiocarcinoma

March 1st 2021

A supplemental new drug application has been submitted to the FDA for ivosidenib tablets as a potential therapeutic option for patients with previously treated, IDH1-mutated cholangiocarcinoma.

Personalized Radioembolization Improves OS Vs Standard Dosing in Advanced HCC

March 1st 2021

Yttrium-90 glass microspheres administered in a personalized, dosimetric approach demonstrated a 16-month improvement in overall survival compared with a standard dosimetric approach in patients with unresectable hepatocellular carcinoma.

Cholangiocarcinoma: Appropriate Diagnostic Work-Up

March 1st 2021

Types of assessments that are used to help appropriately work up a patient suspected of having a bile duct cancer.

Rising Incidence of Cholangiocarcinoma

March 1st 2021

Factors that may contribute to the rise in the number of cholangiocarcinoma cases being reported, as suggested by GI oncologists.